BiotechTube

TNG260 + Pembrolizumab

Phase 1/2Recruiting
0 views this week 0 watching💤 Quiet
Interest: 33/100
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Non Small Cell Lung Cancer

Conditions

Non Small Cell Lung Cancer, Solid Tumors, Adult, Lung Cancer, Lung Adenocarcinoma

Trial Timeline

Jun 12, 2023 → Jun 1, 2026

NCT ID
NCT05887492

About TNG260 + Pembrolizumab

TNG260 + Pembrolizumab is a phase 1/2 stage product being developed by Tango Therapeutics for Non Small Cell Lung Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05887492. Target conditions include Non Small Cell Lung Cancer, Solid Tumors, Adult, Lung Cancer.

What happened to similar drugs?

20 of 20 similar drugs in Non Small Cell Lung Cancer were approved

Approved (20) Terminated (2) Active (0)
✅mouse nerve growth factorSun PharmaceuticalApproved
✅Pemetrexed + CarboplatinEli LillyApproved
✅pemetrexedEli LillyApproved
✅Osimertinib+cisplatin or carboplatin + pemetrexed EditAstraZenecaApproved
✅DurvalumabAstraZenecaApproved
✅Gefitinib + DocetaxelAstraZenecaApproved
✅OsimertinibAstraZenecaApproved

Hype Score Breakdown

Clinical
9
Activity
15
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05887492Phase 1/2Recruiting

Competing Products

20 competing products in Non Small Cell Lung Cancer

See all competitors
ProductCompanyStageHype Score
mRNA-1769ModernaPhase 2
0
BBP-398 with nivolumabBridgeBio PharmaPhase 1
18
Pemetrexed + CarboplatinEli LillyPhase 3
40
Necitumumab + Gemcitabine + CarboplatinEli LillyPhase 2
27
SelpercatinibEli LillyPre-clinical
26
Pemetrexed + Cisplatin + Placebo + PemetrexedEli LillyPhase 3
40
NBTXR3NanobiotixPhase 1/2
33
PemetrexedEli LillyPre-clinical
26
pemetrexed + erlotinibEli LillyPhase 2
35
LY3295668 ErbumineEli LillyPhase 1
29
FYB206 + FYB206 + KeytrudaFormycon AGPhase 3
22
6-Thio-2'-Deoxyguanosine + CemiplimabMAIA BiotechnologyPhase 2
32
6-Thio-2'-Deoxyguanosine + Cemiplimab + Docetaxel + Vinorelbine + Gemcitabine aloneMAIA BiotechnologyPhase 3
37
pemetrexed + cisplatinEli LillyPhase 2
27
gemcitabine + carboplatin + cisplatinEli LillyPhase 2
35
CetuximabEli LillyPhase 1
29
pemetrexed + docetaxelEli LillyPhase 3
40
enzastaurin + pemetrexed + docetaxel + carboplatinEli LillyPhase 2
35
PemCarbo + Pem onlyEli LillyPhase 3
36
TNG456 + abemaciclibEli LillyPhase 1/2
39